Literature DB >> 17338936

Portopulmonary hypertension.

Jason M Golbin1, Michael J Krowka.   

Abstract

As a result of the success of orthotopic liver transplantation, there has been increasing interest in the diagnosis and therapeutic options for the pulmonary vascular complications of hepatic disease. These pulmonary vascular complications range from the hepatopulmonary syndrome, which is characterized by intrapulmonary vascular dilatations, to portopulmonary hypertension (POPH), which is characterized by an elevated pulmonary vascular resistance as a consequence of obstruction to pulmonary arterial blood flow. This review concentrates on POPH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338936     DOI: 10.1016/j.ccm.2006.11.004

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  8 in total

1.  Portopulmonary hypertension.

Authors:  Ravi P Nayak; Dechun Li; George M Matuschak
Journal:  Curr Gastroenterol Rep       Date:  2009-02

2.  Effects of low-dose tolvaptan on electrolyte abnormality and hemodynamic parameters in a liver cirrhosis-associated portopulmonary hypertension patient: A case report.

Authors:  Yoshito Ogihara; Norikazu Yamada; Kaoru Dohi; Akimasa Matsuda; Satoshi Ota; Ken Ishikura; Mashio Nakamura; Masaaki Ito
Journal:  Exp Ther Med       Date:  2016-12-01       Impact factor: 2.447

3.  Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients.

Authors:  Georgios N Kalambokis; Athanasia Mouzaki; Maria Rodi; Konstantinos Pappas; Panagiotis Korantzopoulos; Epameinondas V Tsianos
Journal:  Hepatol Int       Date:  2012-02-02       Impact factor: 6.047

Review 4.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

5.  Management of cardiopulmonary complications of cirrhosis.

Authors:  Prabha Sawant; C Vashishtha; M Nasa
Journal:  Int J Hepatol       Date:  2011-07-19

6.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

7.  Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis.

Authors:  Nicola E Owen; Graeme J Alexander; Sambit Sen; Katherine Bunclark; Gary Polwarth; Joanna Pepke-Zaba; Anthony P Davenport; Nicholas W Morrell; Paul D Upton
Journal:  EBioMedicine       Date:  2020-05-23       Impact factor: 8.143

8.  Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors.

Authors:  Hui-Song Chen; Su-Rong Xing; Wei-Guo Xu; Fan Yang; Xiao-Long Qi; LE-Min Wang; Chang-Qing Yang
Journal:  Exp Ther Med       Date:  2013-01-22       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.